tert-Butyl hexahydropyrazino[2,1-c][1,4]oxazine-8(1H)-carboxylate

Catalog No. :
ACFRTX549
CAS No. :
1630906-78-3
Molecular Formula :
C12H22N2O3
Molecular Weight :
242.32

IUPAC Name:tert-butyl hexahydropyrazino[2,1-c][1,4]oxazine-8(1H)-carboxylate

tert-Butyl hexahydropyrazino[2,1-c][1,4]oxazine-8(1H)-carboxylate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
250mg95%$137.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Nametert-Butyl hexahydropyrazino[2,1-c][1,4]oxazine-8(1H)-carboxylate
IUPAC Nametert-butyl hexahydropyrazino[2,1-c][1,4]oxazine-8(1H)-carboxylate
MDL No.MFCD28502670
Molecular FormulaC12H22N2O3
Molecular Weight242.32
SMILESO=C(N1CC2COCCN2CC1)OC(C)(C)C
InChI KeyNIKUVZOPRNLZMI-UHFFFAOYSA-N
Synonymtert-butyl octahydropiperazino[2,1-c]morpholine-8-carboxylate;Pyrazino[2,1-c][1,4]oxazine-8(1H)-carboxylic acid, hexahydro-, 1,1-dimethylethyl ester;tert-butyl 3,4,6,7,9,9a-hexahydro-1H-pyrazino[2,1-c][1,4]oxazine-8-carboxylate;8-Boc-octahydropyrazino[2,1-c][1,4]oxazine;tert-butyl hexahydropyrazino[2,1-c][1,4]oxazine-8(1h)-carboxylate
CAS No.1630906-78-3
PubChem CID112756686

Safety Data

Pictogram
Toxic
Signal Word
Gefahr
Hazard Statement(s)
H301
Precautionary Statement(s)
P261-P280-P301+P312-P302+P352-P305+P351+P338

Synthetic Route by SureRoute

1. ACFRTX549 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACKYHG531 route compound structure diagram
    ACKYHG5311257998-65-4 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACFRTX549 route product structure diagram
    ACFRTX5491630906-78-3
Inquiry

2. ACFRTX549 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACFRTX549 route product structure diagram
    ACFRTX5491630906-78-3
Inquiry

Comments (0)